


## AMENDMENTS

Kindly add new claims 44-46 and amend claims 11, 13, 33, 36, 37, 38, and 40 as provided in the following Claims Listing.

### Claims Listing:

Claims 1 – 10 (Canceled)

11. (Currently amended) A method for ~~providing sedation, mitigating~~ reducing anxiety, aiding sleep, or inducing sleep ~~or providing anaesthesia~~ in a subject in need thereof, comprising administering to the subject an effective amount of a therapeutic compound, wherein said therapeutic compound is of the formula (Ia):



, in which

$F^2$  is a nitrate group or an organic radical which may be joined in a cyclic ring system with  $G^2$ , and which may contain inorganic counterions;

E is a methylene group;

$G^1$  is a methylene group or does not exist;

$F^1$  is H; and


$G^2$  is joined with  $F^2$  to form a cyclic system or is  $R^N-Z^N$ ; wherein  $R^N$  is an organic radical possessing a heteroaryl group containing a P or S atom, where said P or S is positioned  $\beta$ ,  $\gamma$ , or  $\delta$  to a nitrate group; and  $Z^N$  is  $W^N_{mm}-X^N_{nn}-Y^N_{oo}$ ; wherein

mm, nn, oo are 0 or 1 and  $W^N, X^N, Y^N$  are NH,  $NR^{NN}$ , CO, O, or  $CH_2$ ; wherein

$R^{NN}$  is a  $C_1 - C_{12}$  alkyl group.

12. (Canceled)

13. (Currently amended) A method for ~~providing sedation, mitigating reducing~~  
~~anxiety, aiding sleep, or inducing sleep or providing anaesthesia~~ in a subject in need thereof, comprising administering to said subject an effective amount of a therapeutic compound, wherein said therapeutic compound is of the formula (Ic):



E is  $(R^1R^2C)_m$  and  $G^2-G^1-CF^1F^2-$  is  $R^{19}-(R^3R^4C)_p-(R^{17}R^{18}C)_n-$ ; wherein

each of m, n, and p is an integer from 0 to 10;

$R^{3,17}$   $R^3$  and  $R^{17}$  are each independently hydrogen, a nitrate group, or A; and

$R^{1,4}$   $R^1$  and  $R^4$  are each independently hydrogen, or A;

where A is selected from a substituted or unsubstituted aliphatic group comprising a branched or straight-chain aliphatic moiety having from 1 to 24 carbon atoms in the chain, which optionally may contain O, S,  $NR^6$ , or an unsaturation in the chain, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; an unsubstituted or substituted cyclic aliphatic moiety having from 3 to 7 carbon atoms in the aliphatic ring, which optionally may contain O, S,  $NR^6$ , or an unsaturation in the ring, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; an unsubstituted or substituted aliphatic moiety constituting a linkage of from 0 to 5 carbons, between  $R^1$  and  $R^3$  and/or between  $R^{17}$  and  $R^4$ , which optionally may contain O, S,  $NR^6$ , or an unsaturation in the linkage, and optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; a substituted or unsubstituted aliphatic group comprising a branched, cyclic or straight-chain aliphatic moiety having from 1 to 24 carbon atoms in the chain, containing linkages selected from the group consisting of  $C=O$ ,  $C=S$ , and  $C=NOH$ , which optionally may contain O, S,  $NR^6$ , or an unsaturation in the chain, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; a substituted or unsubstituted aryl group; a substituted or unsubstituted heterocyclic group; an amino group selected from alkylamino, dialkylamino, cyclic amino, diamino, triamino,

arylamino, diarylamino, and alkylarylamino moieties; hydroxy; alkoxy; and a substituted or unsubstituted aryloxy; wherein

X is F, Br, Cl, NO<sub>2</sub>, CH<sub>2</sub>, CF<sub>2</sub>, O, NH, NMe, CN, NHOH, N<sub>2</sub>H<sub>3</sub>, N<sub>2</sub>H<sub>2</sub>R<sup>13</sup>, N<sub>2</sub>HR<sup>13</sup>R<sup>14</sup>, N<sub>3</sub>, S, SCN, SCN<sub>2</sub>H<sub>2</sub>(R<sup>15</sup>)<sub>2</sub>, SCN<sub>2</sub>H<sub>3</sub>(R<sup>15</sup>), SC(O)N(R<sup>15</sup>)<sub>2</sub>, SC(O)NHR<sup>15</sup>, SO<sub>3</sub>M, SH, SR<sup>7</sup>, SO<sub>2</sub>M, S(O)R<sup>8</sup>, S(O)<sub>2</sub>R<sup>9</sup>, S(O)OR<sup>8</sup>, S(O)<sub>2</sub>OR<sup>9</sup>, PO<sub>2</sub>HM, PO<sub>3</sub>HM, PO<sub>3</sub>M<sub>2</sub>, P(O)(OR<sup>15</sup>)(OR<sup>16</sup>), P(O)(OR<sup>16</sup>)(OM), P(O)(R<sup>15</sup>)(OR<sup>8</sup>), P(O)(OM)R<sup>15</sup>, CO<sub>2</sub>M, CO<sub>2</sub>H, CO<sub>2</sub>R<sup>11</sup>, C(O), C(O)R<sup>12</sup>, C(O)(OR<sup>13</sup>), PO<sub>2</sub>H, PO<sub>2</sub>M, P(O)(OR<sup>14</sup>), P(O)(R<sup>13</sup>), SO, SO<sub>2</sub>, C(O)(SR<sup>13</sup>), SR<sup>5</sup>, SSR<sup>7</sup> or SSR<sup>5</sup>;

Y is F, Br, Cl, CH<sub>3</sub>, CF<sub>2</sub>H, CF<sub>3</sub>, OH, NH<sub>2</sub>, NHR<sup>6</sup>, NR<sup>6</sup>R<sup>7</sup>, CN, NHOH, N<sub>2</sub>H<sub>3</sub>, N<sub>2</sub>H<sub>2</sub>R<sup>13</sup>, N<sub>2</sub>HR<sup>13</sup>R<sup>14</sup>, N<sub>3</sub>, S, SCN, SCN<sub>2</sub>H<sub>2</sub>(R<sup>15</sup>)<sub>2</sub>, SCN<sub>2</sub>H<sub>3</sub>(R<sup>15</sup>), SC(O)N(R<sup>15</sup>)<sub>2</sub>, SC(O)NHR<sup>15</sup>, SO<sub>3</sub>M, SH, SR<sup>7</sup>, SO<sub>2</sub>M, S(O)R<sup>8</sup>, S(O)<sub>2</sub>R<sup>9</sup>, S(O)OR<sup>8</sup>, S(O)<sub>2</sub>OR<sup>9</sup>, PO<sub>2</sub>HM, PO<sub>3</sub>M<sub>2</sub>, P(O)(OR<sup>15</sup>)(OR<sup>16</sup>), P(O)(OR<sup>16</sup>)(OM), P(O)(R<sup>15</sup>)(OR<sup>8</sup>), P(O)(OM)R<sup>15</sup>, CO<sub>2</sub>M, CO<sub>2</sub>H, CO<sub>2</sub>R<sup>11</sup>, C(O)R<sup>12</sup>, C(O)(OR<sup>13</sup>), C(O)(SR<sup>13</sup>), SR<sup>5</sup>, SSR<sup>7</sup> or SSR<sup>5</sup>, or does not exist;

each of R<sup>2</sup>, R<sup>5</sup>, R<sup>18</sup>, and R<sup>19</sup> is, independently, hydrogen, A<sub>1</sub> or X-Y;

each of R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup> is, independently, an alkyl or acyl group containing 1-24 carbon atoms, which may contain 1-4 ONO<sub>2</sub> substituents; a C<sub>1</sub> - C<sub>6</sub> connection to R<sup>1</sup> - R<sup>4</sup> in a cyclic derivative, which may contain 1-4 ONO<sub>2</sub> substituents; a hydrogen, a nitrate group, or A;

M is H, Na<sup>+</sup>, K<sup>+</sup>, NH<sub>4</sub><sup>+</sup>, or N<sup>+</sup>H<sub>k</sub>R<sup>11</sup><sub>(4-k)</sub>, where k is 0-3; or other pharmaceutically acceptable counterion;

and with the proviso that when  $m = n = p = 1$  and  $R^{19}, R^2, R^{18}, R^1 = H$  and  $R^{17}, R^3$  are nitrate groups,  $R^4$  is not H.

14. (Previously presented) The method of claim 11, wherein  $F^2$  is a nitrate group; with the proviso that when E and  $G^1$  are methylene groups and  $F^1$  is H,  $G^2$  is not  $R^N-Z^N$ ; wherein

$R^N$  is any aryl or heteroaryl group and  $Z^N$  is  $(CO)_{mm}-X_{nn}^N-Y_{oo}^N$ ; wherein

mm, nn, oo are 0 or 1 and  $X^N, Y^N$  are NH,  $NR^{NN}$ , O or  $CH_2$ ; wherein

$R^{NN}$  is a  $C_1 - C_{12}$  alkyl group.

15. (Previously presented) The method of claim 11, wherein  $F^2$  is a nitrate group; E and  $G^1$  are methylene groups;  $F^1$  is H; and  $G^2$  is  $R^N-Z^N$ ; wherein

$R^N$  is an organic radical possessing an heteroaryl group containing P or S atoms where said P or S are positioned  $\beta, \gamma$ , or  $\delta$  to a nitrate group as identified in formula Ia; and  $Z^N$  is  $W_{mm}^N-X_{nn}^N-Y_{oo}^N$ ; wherein

mm, nn, oo are 0 or 1 and  $W^N, X^N, Y^N$  are NH,  $NR^{NN}$ , CO, O or  $CH_2$ ; wherein

$R^{NN}$  is a  $C_1 - C_{12}$  alkyl group.

16. (Original) The method of claim 13, wherein  $R^{19}$  is X-Y.

17. (Previously presented) The method of claim 16, wherein:

$R^1$  and  $R^3$  are the same or different and selected from H and  $C_1$ - $C_4$  alkyl chains, which chains may include one O linking  $R^1$  and  $R^3$  to form pentosyl, hexosyl, cyclopentyl, or cyclohexyl rings, which rings may optionally bear hydroxyl substituents;

$R^2$  and  $R^4$  are the same or different and selected from H, a nitrate group, a  $C_1$ - $C_4$  alkyl chain, optionally bearing 1-3 nitrate groups, and an acyl group ( $-C(O)R^5$ );

$R^7$  and  $R^{11}$  are the same or different  $C_1 - C_8$  alkyl or  $C_1 - C_8$  acyl;

each of  $R^5, R^6, R^8, R^9, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}$  is, independently, an alkyl group containing 1-12 carbon atoms, which may contain 1-4  $ONO_2$  substituents; or a  $C_1$  or  $C_2$  connection to  $R^1 - R^3$  in a cyclic derivative; and

M is H,  $Na^+$ ,  $K^+$ ,  $NH_4^+$  or  $N^+H_kR^{11}_{(4-k)}$ , where k is 0-3.

18. (Original) The method of claim 17, wherein  $m = 1$ ,  $n = 0$ ,  $p = 1$ .

19. (Previously presented) The method of claim 18, wherein:

X is  $CH_2$ , O, NH, NMe, CN, NHOH,  $N_2H_3$ ,  $N_2H_2R^{13}$ ,  $N_2HR^{13}R^{14}$ ,  $N_3$ , S, SCN,  $SCN_2H_2(R^{15})_2$ ,  $SCN_2H_3(R^{15})$ ,  $SC(O)N(R^{15})_2$ ,  $SC(O)NHR^{15}$ ,  $SO_3M$ , SH,  $SR^7$ ,  $SO_2M$ ,  $S(O)R^8$ ,  $S(O)_2R^9$ ,  $S(O)OR^8$ ,  $S(O)_2OR^9$ ,  $PO_3HM$ ,  $PO_3M_2$ ,  $P(O)(OR^{15})(OR^{16})$ ,  $P(O)(OR^{16})(OM)$ ,  $P(O)(R^{15})(OR^8)$ ,  $P(O)(OM)R^{15}$ ,  $CO_2M$ ,  $CO_2H$ ,  $CO_2R^{11}$ ,  $C(O)$ ,  $C(O)R^{12}$ ,  $C(O)(OR^{13})$ ,  $PO_2M$ ,  $P(O)(OR^{14})$ ,  $P(O)(R^{13})$ , SO,  $SO_2$ ,  $C(O)(SR^{13})$ , or  $SSR^5$ ; and

Y is CN, N<sub>2</sub>H<sub>2</sub>R<sup>13</sup>, N<sub>2</sub>HR<sup>13</sup>R<sup>14</sup>, N<sub>3</sub>, SCN, SCN<sub>2</sub>H<sub>2</sub>(R<sup>15</sup>)<sub>2</sub>, SC(O)N(R<sup>15</sup>)<sub>2</sub>, SC(O)NHR<sup>15</sup>, SO<sub>3</sub>M, SR<sup>4</sup>, SO<sub>2</sub>M, PO<sub>3</sub>HM, PO<sub>3</sub>M<sub>2</sub>, P(O)(OR<sup>15</sup>)(OR<sup>16</sup>), P(O)(OR<sup>16</sup>)(OM), P(O)(R<sup>15</sup>)(OR<sup>8</sup>), P(O)(OM)R<sup>15</sup>, CO<sub>2</sub>M, CO<sub>2</sub>H, CO<sub>2</sub>R<sup>11</sup>, C(O)R<sup>12</sup>, C(O)(SR<sup>13</sup>), SR<sup>5</sup>, or SSR<sup>5</sup>, or does not exist.

20. (Previously presented) The method of claim 18, wherein:  
each of R<sup>5</sup>, R<sup>6</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup> is, independently, an alkyl group containing 1-12 carbon atoms, which may contain 1-4 ONO<sub>2</sub> substituents; or a C<sub>1</sub> or C<sub>2</sub> connection to R<sup>1</sup> - R<sup>3</sup> in a cyclic derivative

X is CH<sub>2</sub>, O, NH, NMe, S, SO<sub>3</sub>M, SH, SR<sup>7</sup>, SO<sub>2</sub>M, S(O)R<sup>8</sup>, S(O)<sub>2</sub>R<sup>9</sup>, S(O)OR<sup>8</sup>, S(O)<sub>2</sub>OR<sup>9</sup>, PO<sub>3</sub>M<sub>2</sub>, P(O)(OR<sup>15</sup>)(OR<sup>16</sup>), P(O)(OR<sup>16</sup>)(OM), P(O)(R<sup>15</sup>)(OR<sup>8</sup>), PO<sub>3</sub>HM or P(O)(OM)R<sup>15</sup>; and

Y is SO<sub>2</sub>M, SO<sub>3</sub>M, PO<sub>3</sub>HM, PO<sub>3</sub>M<sub>2</sub>, P(O)(OR<sup>15</sup>)(OR<sup>16</sup>), P(O)(OR<sup>16</sup>)(OM), SR<sup>5</sup>, SSR<sup>7</sup> or SSR<sup>5</sup>, or does not exist.

21. (Canceled)

22. (Original) The method of claim 13, with the proviso that when m = n = p = 1 and R<sup>19</sup>, R<sup>2</sup>, R<sup>18</sup>, R<sup>1</sup> = H and R<sup>17</sup>, R<sup>3</sup> are nitrate groups, R<sup>4</sup> is not C<sub>1</sub> - C<sub>3</sub> alkyl.

23. (Canceled)

24. (Previously presented) The method of any one of claims 11, 13, 14 or 15, further comprising administering said therapeutic compound with a pharmaceutically acceptable vehicle.

25. (Canceled)

26. (Previously presented) The method of any one of claims 11, 13, 14, or 15, wherein said therapeutic compound modulates levels of the cyclic nucleotides cGMP and/or cAMP in said subject.





27. (Canceled)





28. (Previously presented) The method of any one of claims 11, 13, 14, or 15, wherein said therapeutic compound modulates guanylyl cyclase activity in said subject.





Claims 29-32 (Canceled)











33. (Currently amended) A method of ~~providing sedation or mitigating~~ reducing anxiety, aiding sleep, or inducing sleep in a subject in need thereof, comprising administering to the subject an effective amount of a therapeutic compound selected from the group consisting of:











































IIIal, and




IIIam.



34. (Previously presented) The method of claim 33, wherein said compound has the formula IIIIt:












35. (Previously presented) The method of claim 33, wherein said compound has the formula IIIf:












36. (Currently amended) A method of ~~providing sedation or mitigating~~ reducing anxiety, aiding sleep, or inducing sleep in a subject in need thereof, comprising administering to said subject an effective amount of a therapeutic compound selected from the group consisting of:


















37. (Currently amended) A method of ~~providing sedation~~ reducing anxiety, aiding sleep, or inducing sleep in a subject in need thereof, comprising administering to said subject an effective amount of a therapeutic compound having the formula IVk:











38. (Currently amended) A method of ~~mitigating~~ reducing anxiety, aiding sleep, or inducing sleep in a subject in need thereof, comprising administering to the subject an effective amount of a therapeutic compound selected from the group consisting of:










































39. (Previously presented) The method of claim 38, wherein said compound has the formula Va:



40. (Currently amended) A method of ~~mitigating~~ reducing anxiety, aiding sleep, or inducing sleep in a subject in need thereof, comprising administering to said subject an effective amount of a therapeutic compound having the formula IVr:





41. (Previously presented) The method of claim 11, wherein

$G^2$  is not  $R^N-Z^N$ ; wherein

$R^N$  is any aryl or heteroaryl group and  $Z^N$  is  $(CO)_{mm}-X_{nn}^N-Y_{oo}^N$ ; wherein

mm, nn, oo are 0 or 1 and  $X^N, Y^N$  are NH,  $NR^{NN}$ , O or  $CH_2$ ; wherein

$R^{NN}$  is a  $C_1 - C_{12}$  alkyl group.






42. (Canceled)





43. (Previously presented) The method of claim 16, wherein





X is  $CH_2$ ,  $CF_2$ , O, NH, NMe, S, SCN,  $SCN_2H_2(R^{15})_2$ ,  $SCN_2H_3(R^{15})$ ,  $SC(O)N(R^{15})_2$ ,  $SC(O)NHR^{15}$ ,  $SO_3M$ , SH,  $SR^7$ ,  $SO_2M$ ,  $S(O)R^8$ ,  $S(O)_2R^9$ ,  $S(O)OR^8$ ,  $S(O)_2OR^9$ , C(O), SO,  $SO_2$ ,  $C(O)(SR^{13})$ ,  $SR^5$ ,  $SSR^7$  or  $SSR^5$ ; and





Y is SCN,  $SCN_2H_2(R^{15})_2$ ,  $SCN_2H_3(R^{15})$ ,  $SC(O)N(R^{15})_2$ ,  $SC(O)NHR^{15}$ ,  $SO_3M$ , SH,  $SR^7$ ,  $SO_2M$ ,  $S(O)R^8$ ,  $S(O)_2R^9$ ,  $S(O)OR^8$ ,  $S(O)_2OR^9$ ,  $C(O)(SR^{13})$ ,  $SR^5$ ,  $SSR^7$  or  $SSR^5$ , or does not exist.






















IIIal, and






45. (New) A method of providing sedation or anesthesia in a subject in need thereof, comprising administering to said subject an effective amount of a therapeutic compound selected from the group consisting of:























46. (New) A method of providing sedation or anesthesia in a subject in need thereof, comprising administering to said subject an effective amount of a therapeutic compound selected from the group consisting of:




























Vaf, and



Vag.